The Food and Drug Administration recently approved Augtyro for the treatment of patients ages 12 and older with solid tumors harboring an NTRK gene fusion. With its June approval of Augtyro ...

That drug, Vitrakvi, achieved a 75% response rate in solid tumor patients with NTRK gene fusions and went on ... the strength of evidence that it has a structure capable of maintaining potency ...

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer We compiled a database of patients with NSCLCs that harbor NTRK fusions ... with NSCLCs that harbored ...

“We are proud to deliver on our promise for patients with this significant step forward, providing a treatment option for pediatric and adult patients living with NTRK gene fusion-positive cancers.

FDA grants full approval to Bayer's Vitrakvi for NTRK fusion-positive solid tumors in adults and children. Clinical trials show a 60% overall response rate and median response duration of 43.3 ...

In February 2025, China’s NMPA granted priority review to repotrectinib for the treatment of adult patients with advanced solid tumors that have an NTRK gene fusion. In June 2024, AUGTYRO ...

Vitrakvi, a first-in-class oral TRK inhibitor, was exclusively designed to inhibit against the TRK family of proteins (TRKA, TRKB and TRKC). Pooled efficacy results from three multicenter, open ...

Tropomyosin receptor kinases (TRKs), encoded by neurotrophic receptor tyrosine kinase (NTRK) genes, are involved in cell proliferation, differentiation and apoptosis, and are validated therapeutic ...

VITRAKVI ® is now fully approved for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation ...